Zhejiang Hisoar Pharmaceutical Co Ltd (SHE:002099) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang Hisoar Pharmaceutical Co Ltd (002099)
Zhejiang Hisoar Pharmaceutical Co Ltd (SHE:002099) has a market capitalization of $1.18 Billion (CN¥8.06 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #8341 globally and #2035 in its home market, demonstrating a -4.41% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Hisoar Pharmaceutical Co Ltd's stock price CN¥4.98 by its total outstanding shares 1618715253 (1.62 Billion). Review total liabilities of Zhejiang Hisoar Pharmaceutical Co Ltd to assess the company's total debt and financial obligations.
Zhejiang Hisoar Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Zhejiang Hisoar Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.48 Billion to $1.18 Billion (-5.59% CAGR).
Zhejiang Hisoar Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Hisoar Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.63x
Zhejiang Hisoar Pharmaceutical Co Ltd's market cap is 0.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.48 Billion | $2.46 Billion | $516.59 Million | 1.01x | 4.80x |
| 2016 | $1.78 Billion | $2.43 Billion | $225.02 Million | 0.73x | 7.92x |
| 2017 | $1.22 Billion | $2.31 Billion | $342.22 Million | 0.53x | 3.57x |
| 2018 | $972.65 Million | $2.72 Billion | $605.00 Million | 0.36x | 1.61x |
| 2019 | $1.58 Billion | $2.94 Billion | $770.78 Million | 0.54x | 2.05x |
| 2020 | $1.97 Billion | $2.47 Billion | $319.72 Million | 0.80x | 6.15x |
| 2021 | $1.91 Billion | $2.48 Billion | $95.23 Million | 0.77x | 20.07x |
| 2022 | $1.65 Billion | $2.70 Billion | $88.01 Million | 0.61x | 18.75x |
| 2023 | $1.70 Billion | $2.17 Billion | -$420.06 Million | 0.78x | N/A |
| 2024 | $1.22 Billion | $1.94 Billion | -$330.27 Million | 0.63x | N/A |
Competitor Companies of 002099 by Market Capitalization
Companies near Zhejiang Hisoar Pharmaceutical Co Ltd in the global market cap rankings as of June 19, 2026.
Key companies related to Zhejiang Hisoar Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #555 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #601 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Zhejiang Hisoar Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Zhejiang Hisoar Pharmaceutical Co Ltd's market cap moved from $2.48 Billion to $ 1.18 Billion, with a yearly change of -5.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.18 Billion | -20.19% |
| 2025 | CN¥1.48 Billion | +20.93% |
| 2024 | CN¥1.22 Billion | -28.23% |
| 2023 | CN¥1.70 Billion | +3.19% |
| 2022 | CN¥1.65 Billion | -13.66% |
| 2021 | CN¥1.91 Billion | -2.81% |
| 2020 | CN¥1.97 Billion | +24.53% |
| 2019 | CN¥1.58 Billion | +62.39% |
| 2018 | CN¥972.65 Million | -20.28% |
| 2017 | CN¥1.22 Billion | -31.52% |
| 2016 | CN¥1.78 Billion | -28.14% |
| 2015 | CN¥2.48 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Zhejiang Hisoar Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.18 Billion USD |
| MoneyControl | $1.18 Billion USD |
| MarketWatch | $1.18 Billion USD |
| marketcap.company | $1.18 Billion USD |
| Reuters | $1.18 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Hisoar Pharmaceutical Co Ltd
Zhejiang Hisoar Pharmaceutical Co., Ltd. engages in the manufacture of pharmaceutical products and dyes in China and internationally. The company offers antibiotics, cardiovascular, hypoglycemic, fine chemicals, formulations, intermediates, and other products. It also provides dyestuff, and intermediates of dyestuff and pigment; and manufactures environmental protection related equipment, medical… Read more